MARKHAM, ON, March 9, 2017 /CNW/ - There have been recent reports and media coverage regarding the use of certain unapproved pesticides by some Licensed Producers of cannabis in Canada. MedReleaf is not amongst the companies alleged to have used unapproved agents, nor has it ever used these agents.
As the first and only Licensed Producer with ISO 9001 certification, a global standard for quality management, Canadian patients should remain confident that MedReleaf will continue to lead with practices that exceed the regulatory standard for safety and quality in the Canadian cannabis industry.
As such, the Company is supportive of Cannabis Canada Association's new proposed guideline and standards for Licensed Producers including confirmation of the Company's product testing protocols including bacteria, microbial, aflatoxins, heavy metals and pesticides. To further demonstrate leadership on this issue, MedReleaf will soon begin to provide our patients with access to a simplified Certificate of Analysis (CoA) representing all products being sold.
It is important to note that these testing protocols are not new to MedReleaf. Since the very first batch produced in 2014, all of MedReleaf's products have always been tested by independent, third-party laboratories for over 100 pesticides, heavy metals, aftatoxins, bacteria and microbials. MedReleaf has never been subject to a recall or investigation and the Company uses only products approved by Health Canada. The Company's facilities are regularly inspected by Federal government officials and it is in good standing with Canadian regulators.
We are dedicated to the continued compliance to the Access to Cannabis for Medical Purposes Regulations (ACMPR) and to continuing to set The Medical Grade Standard™ for testing and patient safety.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleafcanada
SOURCE MedReleaf Corp.
For further information: Media contact: Diana McLachlan, Teneo Strategy, 647-334-8572